全文获取类型
收费全文 | 3694篇 |
免费 | 297篇 |
国内免费 | 92篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 63篇 |
妇产科学 | 19篇 |
基础医学 | 306篇 |
口腔科学 | 14篇 |
临床医学 | 217篇 |
内科学 | 1976篇 |
皮肤病学 | 9篇 |
神经病学 | 45篇 |
特种医学 | 62篇 |
外科学 | 439篇 |
综合类 | 176篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 208篇 |
眼科学 | 12篇 |
药学 | 188篇 |
1篇 | |
中国医学 | 66篇 |
肿瘤学 | 279篇 |
出版年
2024年 | 5篇 |
2023年 | 248篇 |
2022年 | 241篇 |
2021年 | 352篇 |
2020年 | 266篇 |
2019年 | 217篇 |
2018年 | 184篇 |
2017年 | 207篇 |
2016年 | 170篇 |
2015年 | 219篇 |
2014年 | 380篇 |
2013年 | 247篇 |
2012年 | 196篇 |
2011年 | 133篇 |
2010年 | 151篇 |
2009年 | 125篇 |
2008年 | 73篇 |
2007年 | 76篇 |
2006年 | 74篇 |
2005年 | 84篇 |
2004年 | 75篇 |
2003年 | 55篇 |
2002年 | 57篇 |
2001年 | 39篇 |
2000年 | 29篇 |
1999年 | 24篇 |
1998年 | 18篇 |
1997年 | 22篇 |
1996年 | 15篇 |
1995年 | 24篇 |
1994年 | 13篇 |
1993年 | 6篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 10篇 |
1987年 | 3篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有4083条查询结果,搜索用时 375 毫秒
41.
Autoimmune hepatitis (AIH) is a severe liver disease affecting all age groups worldwide. Novel basic and clinical aspects of AIH, addressed at a Monothematic Conference in London in September 2015, are highlighted in this review. The diagnosis of AIH relies upon detection of characteristic autoantibodies, hypergammaglobulinemia, and interface hepatitis on liver histology. The International Autoimmune Hepatitis Group (IAIHG) has devised diagnostic scoring systems to help in comparative studies and clinical practice. AIH arises in a genetically predisposed host, when yet unknown triggers – such an encounter with a pathogen – lead to a T cell-mediated immune response targeting liver autoantigens. This immune response is inadequately controlled because regulatory mechanisms are impaired. The mainstay of treatment for AIH is immunosuppression, which should be instituted as soon as the diagnosis is made. Standard treatment regimens include relatively high doses of predniso(lo)ne, which are tapered gradually as azathioprine is introduced. Recent guidelines have described newer treatment regimens and have tightened the goal of therapy to complete normalization of biochemical, serological and histological parameters. Mycophenolate mofetil, calcineurin inhibitors, mTOR inhibitors and biological agents are potential salvage therapies, but should be reserved for selected non-responsive patients and administered only in experienced centers. Liver transplantation is a life-saving option for those patients who progress to end-stage liver disease. Further dissection of cellular and molecular pathways involved in AIH pathogenesis is likely to lead to the discovery of novel, tailored and better tolerated therapies. 相似文献
42.
The combination of first generation protease inhibitors, telaprevir or boceprevir with pegylated interferon and ribavirin has significantly improved response rates when compared to pegylated interferon and ribavirin alone. While safe and effective for many patients, the potential of current DAA based therapy has been limited by tolerability, especially in those with extensive co-morbidities. Newer therapies, likely with improved efficacy and safety profiles are under development, however the timing of availability of these agents remains speculative. The choice to treat with currently available therapy or to wait for newer therapy is complex. These decisions require understanding of unique patient characteristics as well as safety and efficacy of both available therapy and new therapies undergoing investigation. 相似文献
43.
44.
45.
46.
《Journal of Crohn's and Colitis》2013,7(2):120-128
BackgroundDifferentiation between predominantly inflammatory versus fibrous-predominant lesions is particularly important in order to decide the optimal therapy in patients with refractory symptoms in Crohn's disease (CD).ObjectiveThe purpose of this investigation was to evaluate the accuracy of several US parameters, especially of contrast-enhanced US, for evaluation of mural inflammation in CD, with histopathology as the reference.Materials and methodsPreoperative ultrasound examination, including contrast-enhanced ultrasound (CEUS) was performed in 25 consecutive patients with Crohn's disease undergoing elective bowel resection. Ultrasound variables, such as wall thickness, transmural complications, colour Doppler grade, quantitative analysis of the enhancement and the presence and severity of strictures, were prospectively evaluated and compared with the histopathology results. Histopathology grading of acute inflammation using the acute inflammatory score and the degree of fibrostenosis was performed in each segment and the results were compared with all the US variables as well as with a previously defined ultrasound score system for inflammatory and fibrostenotic changes.Results28 segments were analysed. In pathology analysis there were 12 predominantly inflammatory segments, 9 predominantly fibrostenotic and 7 compound lesions. When the pathology score was dichotomised into two groups (inflammatory and fibrostenotic) the number of stenoses correctly classified by US was 23 out 28, with a substantial agreement (kappa = 0.632). There was a good correlation between the sonographic and pathology scores, both inflammation (Spearman's, r = 0.53) and fibrostenosis (Spearman's, r = 0.50). Transmural complications, colour Doppler grade and percentage of increase in contrast enhancement were significantly associated with the pathology inflammatory score (p = 0.018, p = 0.036 and p = 0.005, respectively). There was a significantly negative association between the colour Doppler grade and the pathologic fibrostenotic score.ConclusionsUltrasound, including CEUS, can be a useful tool for distinguishing inflammatory from fibrostenotic lesions in CD. This information can be useful in the management of CD. 相似文献
47.
48.
49.
50.